相关实验视频
Updated: Jul 22, 2025

08:25
Transverse Aortic Constriction in Mice
Published on: April 21, 2010
67.3K
跨膜蛋白117 knockdown 保护抗抗血管酶II诱导的心脏缩
Yi Yang1,2,3, Xinquan Wang1,2,3, Peng Yan1,2,3
1Department of Cardiology, The First Affiliated Hospital, Chengdu Medical College, Chengdu, 610500, Sichuan, China.
概括
跨膜蛋白117 (TMEM117) 通过增加氧化应激和线粒体损伤,促进心脏缩. 降低TMEM117的调节可能为治疗心脏缩提供了一种新的治疗方法.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 线粒体生物学 线粒体生物学
背景情况:
- 病理性心脏缩与线粒体功能障碍有关.
- 跨膜蛋白117 (TMEM117) 影响线粒体膜的潜力和功能.
- TMEM117在血管素II (Ang-II) 诱导的心脏缩中的作用尚不清楚.
研究的目的:
- 为了研究TMEM117在Ang-II诱导的心脏缩中的作用.
- 为了确定TMEM117调制是否影响氧化应激,内质网膜应激和心脏缩中的线粒体损伤.
主要方法:
- 使用心脏特异性TMEM117敲击小鼠和对照小鼠.
- 使用 ангиотензин II 输液诱导心脏缩.
- 使用小干扰RNA和腺病毒载体在体内和新生儿小鼠心室肌细胞 (NMVM) 中实现了TMEM117的淘汰和过度表达.
主要成果:
- TMEM117在多变性心脏和心肌细胞中被上调.
- TMEM117缺乏减轻了Ang-II诱导的心脏缩,氧化应激,内分泌网膜应激和线粒体损伤.
- TMEM117的过度表达加剧了这些病理变化.
结论:
- TMEM117的升调有助于心脏缩的发展.
- 降低TMEM117的调节可能代表心脏缩的新疗法策略.
- TMEM117在通过氧化和线粒体通路调解Ang-II诱导的心脏缩方面发挥着重要作用.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Antihypertensive Drugs: Angiotensin II Receptor Blockers
782
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
782
Antihypertensive Drugs: Direct Renin Inhibitors
687
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
687
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
692
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
692
Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16

